.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Medtronic
Argus Health
McKinsey
Covington
Novartis
Mallinckrodt
Express Scripts
AstraZeneca
Julphar

Generated: December 12, 2017

DrugPatentWatch Database Preview

ACZONE Drug Profile

« Back to Dashboard

Which patents cover Aczone, and what generic alternatives are available?

Aczone is a drug marketed by Allergan and Allergan Inc and is included in two NDAs. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has fifty patent family members in twenty-three countries.

The generic ingredient in ACZONE is dapsone. There are eight drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the dapsone profile page.
Drug patent expirations by year for ACZONE

Pharmacology for ACZONE

Ingredient-typeSulfones
Drug ClassSulfone

Medical Subject Heading (MeSH) Categories for ACZONE

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
AllerganACZONEdapsoneGEL;TOPICAL021794-001Jul 7, 2005ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllerganACZONEdapsoneGEL;TOPICAL021794-001Jul 7, 2005ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
AllerganACZONEdapsoneGEL;TOPICAL021794-001Jul 7, 2005ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ACZONE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016► Subscribe► Subscribe
AllerganACZONEdapsoneGEL;TOPICAL021794-001Jul 7, 2005► Subscribe► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016► Subscribe► Subscribe
Allergan IncACZONEdapsoneGEL;TOPICAL207154-001Feb 24, 2016► Subscribe► Subscribe
AllerganACZONEdapsoneGEL;TOPICAL021794-001Jul 7, 2005► Subscribe► Subscribe
AllerganACZONEdapsoneGEL;TOPICAL021794-001Jul 7, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ACZONE

Drugname Dosage Strength RLD Submissiondate
dapsoneGel7.5%Aczone2/13/2017

International Patent Family for Tradename: ACZONE

Country Document Number Estimated Expiration
Australia4261097► Subscribe
Eurasian Patent Organization008022► Subscribe
Slovenia1485059► Subscribe
Iceland7419► Subscribe
Austria353628► Subscribe
Portugal1485059► Subscribe
World Intellectual Property Organization (WIPO)9810746► Subscribe
Canada2265461► Subscribe
Australia2002306767► Subscribe
China105246457► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Medtronic
US Department of Justice
Federal Trade Commission
Mallinckrodt
Chubb
Baxter
Healthtrust
Accenture
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot